SOD1 and ovarian cancer: This approach might, in particular, be applied to treat MDR tumors because, for example, SOD1 is a therapeutic target of TM [6] and inhibition of SOD1 was shown to restore the cisplatin-sensitivity in resistant ovarian cancer cells [45].